{"ticker": {"uuid": "d26d60f2-b3ee-4ed5-9030-bc7c365624e7", "symbol": "SABS", "name": "SAB Biotherapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQMm56MHVYQ1Bnc3FiVHpSNEFxaXRieHJyNXZVUVVJaUhNQUI3VWpQb3U0VlFPTUd0M2I3aXBZV0k0UUM3aEZ3Xy0zeFlqSDAtME9kclhvQmYxVXRiWlpYR0I3NXFUQUV6bnFQckNiZmxVN1BOcUZOZTVFRWtCSXNOTUNSZVFGTWJkYXI5THlLOUQyQy03SzJnUU5FWEZERTRyMmk0Qw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T15:43:07+00:00", "published_display": "15 Jul 2026 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026", "summary": "This article provides an updated analysis of SAB Biotherapeutics (SABS) short interest and short float as of July 2026. As of June 30, 2026, the short interest was 3.77 million shares, representing 5.33% of the public float, and marked a 31.17% increase since the prior report. Th", "url": "https://www.marketbeat.com/stocks/NASDAQ/SABS/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T22:46:19", "published_display": "10 Jul 2026 22:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026 $SABS", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5MM0hGX3RZQXRXVElXbTBpbkpOOUlDcUVCdkEwZDFaUks5YXMtNldIN2I0dF92Z20xQ0ZCQXljanBXS19Vems2TEE3Qm5XTjZHaXlLM0F3aGdsVC1hUEhfRGVkTTl1bnk1bGMtRmVR?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes", "summary": "Breakthrough T1D has awarded a grant to support the PRISE-hATG study, which will evaluate SAB-142 for preserving beta cell function in patients with Stage 3 Type 1 Diabetes (T1D). SAB Biotherapeutics will co-fund this trial, designed to assess SAB-142's ability to preserve endoge", "url": "https://www.tradingview.com/news/tradingview:a4c48f4889d80:0-breakthrough-t1d-funds-prise-hatg-to-study-sab-142-in-stage-3-type-1-diabetes/", "source_name": "TradingView", "published_at": "2026-07-07T12:13:07", "published_display": "07 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial", "summary": "SAB Biotherapeutics has received a grant from Breakthrough T1D to support the PRISE-hATG clinical study of its lead candidate, SAB-142, for Stage 3 Type 1 Diabetes (T1D). This trial will evaluate SAB-142 in patients diagnosed between 100 days and two years, complementing SAB BIO'", "url": "https://www.stocktitan.net/sec-filings/SABS/8-k-sab-biotherapeutics-inc-reports-material-event-348ddda5d65f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:13:07", "published_display": "07 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/why-h-c-wainwright-bullish-220812002.html", "source_name": "Insider Monkey", "published_at": "2026-07-05T22:08:12+00:00", "published_display": "05 Jul 2026 22:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Overlooked Penny Stocks to Buy Right Now", "summary": "This article highlights SAB Biotherapeutics, Inc. (NASDAQ: SABS) as an overlooked penny stock with significant upside potential. Analysts from Barclays and H.C. Wainwright have issued bullish ratings, citing a large market opportunity for its lead diabetes program, SAB-142, and r", "url": "https://www.insidermonkey.com/blog/5-overlooked-penny-stocks-to-buy-right-now-1795388/2/", "source_name": "Insider Monkey", "published_at": "2026-07-04T23:10:53", "published_display": "04 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings", "summary": "This page provides access to SAB Biotherapeutics, Inc. (SABSW) financial disclosures and SEC filings, including corporate presentations, earnings reports, and quarterly reports from 2023 to 2026. The documents highlight the company's progress with SAB-142, a disease-modifying the", "url": "https://www.tradingview.com/symbols/BOATS-SABSW/documents/", "source_name": "TradingView", "published_at": "2026-07-03T19:09:24", "published_display": "03 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SAB Biotherapeutics, Inc. \u2013 NASDAQ:SABS", "summary": "This article displays the \"Price to sales forward\" metric for SAB Biotherapeutics, Inc. (NASDAQ: SABS) on the TradingView platform. It shows the company's stock information, along with various navigation and product links typical of a financial charting website, but no specific f", "url": "https://www.tradingview.com/symbols/NASDAQ-SABS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T07:09:24", "published_display": "03 Jul 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)", "summary": "Barclays initiated coverage on SAB Biotherapeutics Inc. (SABS) with an Overweight rating and a $13 price target, projecting over 235% upside. Analyst Eliana Merle highlights SAB-142's potential as a disease-altering treatment for type 1 diabetes and believes the anticipated Phase", "url": "https://finance.yahoo.com/markets/stocks/articles/barclays-assigns-overweight-rating-sab-163449158.html", "source_name": "Market source", "published_at": "2026-06-30T16:40:02", "published_display": "30 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell Microcap Index", "summary": "SAB Biotherapeutics, Inc. (NasdaqCM: SABS) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical firm focusing on human polyclonal immunotherapeutic antibodies for immunology disorders, with its lead product candidate, SAB-142, targeting ", "url": "https://www.marketscreener.com/news/sab-biotherapeutics-inc-nasdaqcm-sabs-added-to-russell-microcap-index-ce7f5fdedd88f627", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:11:46", "published_display": "29 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Value Benchmark", "summary": "SAB Biotherapeutics, Inc. (NasdaqCM: SABS) has been added to the Russell 3000E Value Benchmark. The company is a clinical-stage biopharmaceutical company focusing on developing human polyclonal immunotherapeutic antibodies for immunology disorders, particularly Type 1 Diabetes. T", "url": "https://www.marketscreener.com/news/sab-biotherapeutics-inc-nasdaqcm-sabs-added-to-russell-3000e-value-benchmark-ce7f5fddd988f125", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:40:06", "published_display": "29 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of SAB Biotherapeutics, Inc. \u2013 NASDAQ:SABSW", "summary": "The article provides information regarding the \"Price to book forward\" for SAB Biotherapeutics, Inc. (NASDAQ: SABSW) as listed on TradingView. It appears to be a financial data page showing a specific metric for the company, indicating key financial details for investors.", "url": "https://www.tradingview.com/symbols/NASDAQ-SABSW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:40:03", "published_display": "27 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SAB Biotherapeutics, Inc. \u2013 NASDAQ:SABSW", "summary": "The article focuses on the \"Price to sales forward\" metric for SAB Biotherapeutics, Inc. (NASDAQ: SABSW). It appears to be a financial data page from TradingView, providing an overview of the company's financial data. The content is sparse, indicating that specific financial figu", "url": "https://www.tradingview.com/symbols/NASDAQ-SABSW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:40:39", "published_display": "27 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of SAB Biotherapeutics, Inc. \u2013 NASDAQ:SABS", "summary": "This article provides the enterprise value to EBITDA forward for SAB Biotherapeutics, Inc. (NASDAQ: SABS). It is presented on the TradingView platform, which offers financial data and tools for market analysis. The content indicates the data was \"Made by humans\" and is available ", "url": "https://www.tradingview.com/symbols/NASDAQ-SABS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:40:39", "published_display": "27 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 SAB Biotherapeutics Inc For: 26 June By Investing.com", "summary": "This article announces the filing of a Form 4 for SAB Biotherapeutics Inc on June 26, as reported by Investing.com. It is a brief corporate news item confirming a regulatory filing for the company. The article also provides a snapshot of various market data including indices, com", "url": "https://au.investing.com/news/stock-market-news/form-4-sab-biotherapeutics-inc-for-26-june-93CH-4507423", "source_name": "Investing.com Australia", "published_at": "2026-06-27T01:40:15", "published_display": "27 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity", "summary": "SAB Biotherapeutics, Inc.'s Chief Medical Officer, Alexandra Kropotova, reported a Form 4 detailing a tax-withholding disposition of 988 common stock shares related to restricted stock unit vesting. After this transaction, she holds 42,308 shares, which includes 5,150 unvested RS", "url": "https://www.stocktitan.net/sec-filings/SABS/form-4-sab-biotherapeutics-inc-insider-trading-activity-57b71400294e.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:40:15", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SABS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for SAB Biotherapeutics, Inc. (SABS) stock, including its price target, analyst ratings, and financial data. According to 12 analysts, the stock has a 1-year price forecast, with a current price of $3.80 and a maximum estimate of $16.00 and minimu", "url": "https://www.tradingview.com/symbols/NASDAQ-SABS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T15:40:39", "published_display": "26 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:SABS)", "summary": "This article provides an overview of SAB Biotherapeutics, Inc. (NASDAQ: SABS) financials, stock performance, and analyst forecasts. As of the article's date, SABS stock is trading at $3.80 USD, having decreased by 1.81% in the past 24 hours but showing a 103.21% increase over the", "url": "https://www.tradingview.com/symbols/NASDAQ-SABS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:40:39", "published_display": "26 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target", "summary": "Barclays has initiated coverage on SAB Biotherapeutics with an Overweight rating and set a price target of $13. This indicates a positive outlook from the investment bank regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71964792/barclays-initiates-sab-biotherapeutics-at-overweight-with-13-price-target?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-24T17:11:46", "published_display": "24 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 By Investing.com", "summary": "Barclays has initiated coverage on SAB Biotherapeutics Inc. (NASDAQ: SABS) with an Overweight rating and a $13 price target, citing the significant potential of its lead candidate, SAB-142, for type 1 diabetes prevention. The firm believes SAB-142 could address a market exceeding", "url": "https://ng.investing.com/news/stock-market-news/barclays-initiates-sab-biotherapeutics-stock-at-overweight-pt-13-93CH-2571809", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T15:09:59", "published_display": "24 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13", "summary": "Barclays has initiated coverage on SAB Biotherapeutics Inc. (NASDAQ:SABS) with an Overweight rating and a $13.00 price target, citing the potential of its lead candidate SAB-142 for type 1 diabetes prevention, which they estimate could exceed $4 billion in opportunity. Despite th", "url": "https://www.investing.com/news/analyst-ratings/barclays-initiates-sab-biotherapeutics-stock-at-overweight-pt-13-93CH-4757840", "source_name": "Investing.com", "published_at": "2026-06-24T11:40:06", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics Inc (SABS) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" score for SAB Biotherapeutics Inc (SABS) as part of TradingKey's stock analysis. As of June 23, 2026, the company's institutional confidence score is 7.00. The article details major institutional shareholders and their sharehold", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sabs/sentiment", "source_name": "TradingKey", "published_at": "2026-06-23T02:11:11", "published_display": "23 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) 44th Annual J.P. Morgan Healthcare Conference Summary", "summary": "SAB Biotherapeutics presented an overview of its strategic vision and clinical focus for its lead drug, SAB-142, at the 44th Annual J.P. Morgan Healthcare Conference. The drug, a fully human anti-thymocyte immunoglobulin, is in a pivotal Phase II-B trial for type 1 diabetes and a", "url": "https://quartr.com/events/sab-biotherapeutics-inc-sabs-44th-annual-j-p-morgan-healthcare-conference_FPWAfxVL", "source_name": "Quartr", "published_at": "2026-06-19T12:40:59", "published_display": "19 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article attempts to provide a revenue breakdown for SAB Biotherapeutics Inc (SABS) but states that the relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder page o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sabs/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T05:39:09", "published_display": "19 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of SAB Biotherapeutics Inc (SABS), listing major shareholders like Vivo Capital, LLC and Commodore Capital LP, and categorizing shareholder types. It also provides a historical overview of institutional shareholding from 2023Q4 to 20", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sabs/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T04:39:09", "published_display": "19 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics shareholders elect directors and approve auditor at annual meeting", "summary": "SAB Biotherapeutics shareholders elected four Class II directors\u2014Dr. David Zaccardelli, Katie Ellias, David Link, and Andrew Moin\u2014and ratified EisnerAmper LLP as their independent public accounting firm for the fiscal year ending December 31, 2026, at the company's 2026 Annual Me", "url": "https://www.investing.com/news/sec-filings/sab-biotherapeutics-shareholders-elect-directors-and-approve-auditor-at-annual-meeting-93CH-4751171", "source_name": "Investing.com", "published_at": "2026-06-19T01:39:32", "published_display": "19 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Adjusts Price Target on SAB Biotherapeutics to $16 From $14, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/chardan-adjusts-price-target-sab-105123281.html", "source_name": "MT Newswires", "published_at": "2026-06-17T10:51:23+00:00", "published_display": "17 Jun 2026 10:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies raises SAB Biotherapeutics price target on FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPeDh6OGIzSUlFdXNpZmxtZHR4UEdJRUVwX3FaQS11Y0ZIeE5GVFltNGtGRnZNTUxGMzZaRkhtRVRuS2o3R3pfMnZuMHA5UFlxbDBic0x0NFZ3OVprU0RVSWFFYlJ3cmV3ZmJrQ0RYdDhrRFZKSlBxaDR1c05QVHloS0RCREpfZkJQOTY1V2pLT2Q0aENfZEJvTTByb01YMkp6MXQ1dVFQcDVmWGxrZ21rSHRTRS1CdWV4enU1UWhxVTE0c0k?oc=5", "source_name": "Investing.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SABS - SAB Biotherapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE0tNmltakhIblRrcHNmNENoSWhNYWUzbkJ2bG9EVnRZWDZDTkRHcnViUHBFUUttRnlIN29ZaEFsb3NKUXN2WGc?oc=5", "source_name": "Finviz", "published_at": "2026-05-29T12:43:39+00:00", "published_display": "29 May 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citigroup-initiates-sab-biotherapeutics-buy-105511656.html", "source_name": "MT Newswires", "published_at": "2026-05-22T10:55:11+00:00", "published_display": "22 May 2026 10:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Initiates SAB Biotherapeutics at Buy With $11 Price Target", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/jefferies-initiates-sab-biotherapeutics-buy-100833405.html", "source_name": "MT Newswires", "published_at": "2026-05-20T10:08:33+00:00", "published_display": "20 May 2026 10:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQQ2FVcEIwYlRuWmFaMEtjNFdoTDRYcnZiT2ZhSlJVUUh3TVNjRU9mZEdJei0yWEdHVC01ZTNWWUdVM0RsRXhteElHSVNIYWVQZGpiQnpWUDVYbmZVX0NWNndGYWRXRXFTREZDaFFDbndJbkJLX01QRURoMGZubkotSE1iU3ZyZUR6ZXdmdzRveVFLRHRQcWlDV0J0VEtVRXpDUDYtbQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MRNA, INO, SABS, NVAX Stocks Jump Premarket: Deadly Hantavirus Reaches US After Cruise Ship Outbreak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOd0VqbG16c1dPY0swVTFUVVkzRjU2ellTUGlxVmFwY1V6S21WZ1FxOU5rYk1HWlltMlpBOXliN0lxNzZEX21jeXBKNGNSVUpfZUhabDBZcEdsLUxKQ01QWHUzMmN0OFFneEhSeTZkZW5uSDUyNEdQOGxfTUF4VmZETHFCYm01bDhIYTFERnl1MkM5djIxYUNGbHhWbWl3ck1XS3k5cmYtR3ItUDZKVUxqTjdxYm92Q0xnWDktb0lQNXQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-11T08:25:52+00:00", "published_display": "11 May 2026 08:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdXYtRGl6NTZ0aV8wQWxiY0ZwaVFTTzRZbkxLcnNFRnMyWmdrMVFEaDJjdHlWWVNZeEJXT0VqU19QVHBlWTNBV29EX182REkteG1rcm5ZTldaZzBhZDlLRkJ0UW1ELUM3T08tLVluN1VsYS01X29NVU5adkxiS1Q1cnlUYzI2X0xmdEQwUk9qc0FkOXJFOVRFa2l1bUJUY3NJX1hjQmZKZ0EzRVlpelhGUmg3UmZRUjdz?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SAB Biotherapeutics (SABS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $SABS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFBkdFM5U19IN05VeUh4VDBJcTNxRDFMU0FFNDA3LUgtTVpKdTFUelltMWVOSTdmUHNiRlBkQnVRUFVRWHZZQmZGNzUwU1NZTUdROWdKUV9Bakg3eUU2SElIcmhBQ0diQS1I?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-10T02:21:07+00:00", "published_display": "10 Jul 2025 02:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) Stock Chart and Price History 2026 $SABS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE4tZU1uVzdKSjdTa2NlRzR6Z1cyeDdFVDN3S0NQZmhwTXhjZFVzY25DYTNrbEc5WFRCOXMtUDhLRDhhODU2dC1IQ1I0VzNuNXhQV05Ob2Vhc3BhdDFwcUZBM2Jn?oc=5", "source_name": "MarketBeat", "published_at": "2021-10-25T17:14:21+00:00", "published_display": "25 Oct 2021 17:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) Stock Price, News & Analysis $SABS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE84ZndvdlZSUlZ5ME9TR2N1LXVOYmlmNFpWOEpOVk94MUdqOFh4VGJReGhCbzE1S0NJNTZxWVdBWkhjMjBzQnV0TFJUal9uV1Y3VlU4VUZiZU5OQQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-10-25T16:41:46+00:00", "published_display": "25 Oct 2021 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQMm56MHVYQ1Bnc3FiVHpSNEFxaXRieHJyNXZVUVVJaUhNQUI3VWpQb3U0VlFPTUd0M2I3aXBZV0k0UUM3aEZ3Xy0zeFlqSDAtME9kclhvQmYxVXRiWlpYR0I3NXFUQUV6bnFQckNiZmxVN1BOcUZOZTVFRWtCSXNOTUNSZVFGTWJkYXI5THlLOUQyQy03SzJnUU5FWEZERTRyMmk0Qw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T15:43:07+00:00", "published_display": "15 Jul 2026 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026", "summary": "This article provides an updated analysis of SAB Biotherapeutics (SABS) short interest and short float as of July 2026. As of June 30, 2026, the short interest was 3.77 million shares, representing 5.33% of the public float, and marked a 31.17% increase since the prior report. Th", "url": "https://www.marketbeat.com/stocks/NASDAQ/SABS/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T22:46:19", "published_display": "10 Jul 2026 22:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026 $SABS", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5MM0hGX3RZQXRXVElXbTBpbkpOOUlDcUVCdkEwZDFaUks5YXMtNldIN2I0dF92Z20xQ0ZCQXljanBXS19Vems2TEE3Qm5XTjZHaXlLM0F3aGdsVC1hUEhfRGVkTTl1bnk1bGMtRmVR?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes", "summary": "Breakthrough T1D has awarded a grant to support the PRISE-hATG study, which will evaluate SAB-142 for preserving beta cell function in patients with Stage 3 Type 1 Diabetes (T1D). SAB Biotherapeutics will co-fund this trial, designed to assess SAB-142's ability to preserve endoge", "url": "https://www.tradingview.com/news/tradingview:a4c48f4889d80:0-breakthrough-t1d-funds-prise-hatg-to-study-sab-142-in-stage-3-type-1-diabetes/", "source_name": "TradingView", "published_at": "2026-07-07T12:13:07", "published_display": "07 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial", "summary": "SAB Biotherapeutics has received a grant from Breakthrough T1D to support the PRISE-hATG clinical study of its lead candidate, SAB-142, for Stage 3 Type 1 Diabetes (T1D). This trial will evaluate SAB-142 in patients diagnosed between 100 days and two years, complementing SAB BIO'", "url": "https://www.stocktitan.net/sec-filings/SABS/8-k-sab-biotherapeutics-inc-reports-material-event-348ddda5d65f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:13:07", "published_display": "07 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/why-h-c-wainwright-bullish-220812002.html", "source_name": "Insider Monkey", "published_at": "2026-07-05T22:08:12+00:00", "published_display": "05 Jul 2026 22:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Overlooked Penny Stocks to Buy Right Now", "summary": "This article highlights SAB Biotherapeutics, Inc. (NASDAQ: SABS) as an overlooked penny stock with significant upside potential. Analysts from Barclays and H.C. Wainwright have issued bullish ratings, citing a large market opportunity for its lead diabetes program, SAB-142, and r", "url": "https://www.insidermonkey.com/blog/5-overlooked-penny-stocks-to-buy-right-now-1795388/2/", "source_name": "Insider Monkey", "published_at": "2026-07-04T23:10:53", "published_display": "04 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings", "summary": "This page provides access to SAB Biotherapeutics, Inc. (SABSW) financial disclosures and SEC filings, including corporate presentations, earnings reports, and quarterly reports from 2023 to 2026. The documents highlight the company's progress with SAB-142, a disease-modifying the", "url": "https://www.tradingview.com/symbols/BOATS-SABSW/documents/", "source_name": "TradingView", "published_at": "2026-07-03T19:09:24", "published_display": "03 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SAB Biotherapeutics, Inc. \u2013 NASDAQ:SABS", "summary": "This article displays the \"Price to sales forward\" metric for SAB Biotherapeutics, Inc. (NASDAQ: SABS) on the TradingView platform. It shows the company's stock information, along with various navigation and product links typical of a financial charting website, but no specific f", "url": "https://www.tradingview.com/symbols/NASDAQ-SABS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T07:09:24", "published_display": "03 Jul 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)", "summary": "Barclays initiated coverage on SAB Biotherapeutics Inc. (SABS) with an Overweight rating and a $13 price target, projecting over 235% upside. Analyst Eliana Merle highlights SAB-142's potential as a disease-altering treatment for type 1 diabetes and believes the anticipated Phase", "url": "https://finance.yahoo.com/markets/stocks/articles/barclays-assigns-overweight-rating-sab-163449158.html", "source_name": "Market source", "published_at": "2026-06-30T16:40:02", "published_display": "30 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell Microcap Index", "summary": "SAB Biotherapeutics, Inc. (NasdaqCM: SABS) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical firm focusing on human polyclonal immunotherapeutic antibodies for immunology disorders, with its lead product candidate, SAB-142, targeting ", "url": "https://www.marketscreener.com/news/sab-biotherapeutics-inc-nasdaqcm-sabs-added-to-russell-microcap-index-ce7f5fdedd88f627", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:11:46", "published_display": "29 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Value Benchmark", "summary": "SAB Biotherapeutics, Inc. (NasdaqCM: SABS) has been added to the Russell 3000E Value Benchmark. The company is a clinical-stage biopharmaceutical company focusing on developing human polyclonal immunotherapeutic antibodies for immunology disorders, particularly Type 1 Diabetes. T", "url": "https://www.marketscreener.com/news/sab-biotherapeutics-inc-nasdaqcm-sabs-added-to-russell-3000e-value-benchmark-ce7f5fddd988f125", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:40:06", "published_display": "29 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of SAB Biotherapeutics, Inc. \u2013 NASDAQ:SABSW", "summary": "The article provides information regarding the \"Price to book forward\" for SAB Biotherapeutics, Inc. (NASDAQ: SABSW) as listed on TradingView. It appears to be a financial data page showing a specific metric for the company, indicating key financial details for investors.", "url": "https://www.tradingview.com/symbols/NASDAQ-SABSW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:40:03", "published_display": "27 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SAB Biotherapeutics, Inc. \u2013 NASDAQ:SABSW", "summary": "The article focuses on the \"Price to sales forward\" metric for SAB Biotherapeutics, Inc. (NASDAQ: SABSW). It appears to be a financial data page from TradingView, providing an overview of the company's financial data. The content is sparse, indicating that specific financial figu", "url": "https://www.tradingview.com/symbols/NASDAQ-SABSW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:40:39", "published_display": "27 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of SAB Biotherapeutics, Inc. \u2013 NASDAQ:SABS", "summary": "This article provides the enterprise value to EBITDA forward for SAB Biotherapeutics, Inc. (NASDAQ: SABS). It is presented on the TradingView platform, which offers financial data and tools for market analysis. The content indicates the data was \"Made by humans\" and is available ", "url": "https://www.tradingview.com/symbols/NASDAQ-SABS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:40:39", "published_display": "27 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 SAB Biotherapeutics Inc For: 26 June By Investing.com", "summary": "This article announces the filing of a Form 4 for SAB Biotherapeutics Inc on June 26, as reported by Investing.com. It is a brief corporate news item confirming a regulatory filing for the company. The article also provides a snapshot of various market data including indices, com", "url": "https://au.investing.com/news/stock-market-news/form-4-sab-biotherapeutics-inc-for-26-june-93CH-4507423", "source_name": "Investing.com Australia", "published_at": "2026-06-27T01:40:15", "published_display": "27 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity", "summary": "SAB Biotherapeutics, Inc.'s Chief Medical Officer, Alexandra Kropotova, reported a Form 4 detailing a tax-withholding disposition of 988 common stock shares related to restricted stock unit vesting. After this transaction, she holds 42,308 shares, which includes 5,150 unvested RS", "url": "https://www.stocktitan.net/sec-filings/SABS/form-4-sab-biotherapeutics-inc-insider-trading-activity-57b71400294e.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:40:15", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SABS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for SAB Biotherapeutics, Inc. (SABS) stock, including its price target, analyst ratings, and financial data. According to 12 analysts, the stock has a 1-year price forecast, with a current price of $3.80 and a maximum estimate of $16.00 and minimu", "url": "https://www.tradingview.com/symbols/NASDAQ-SABS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T15:40:39", "published_display": "26 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:SABS)", "summary": "This article provides an overview of SAB Biotherapeutics, Inc. (NASDAQ: SABS) financials, stock performance, and analyst forecasts. As of the article's date, SABS stock is trading at $3.80 USD, having decreased by 1.81% in the past 24 hours but showing a 103.21% increase over the", "url": "https://www.tradingview.com/symbols/NASDAQ-SABS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:40:39", "published_display": "26 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target", "summary": "Barclays has initiated coverage on SAB Biotherapeutics with an Overweight rating and set a price target of $13. This indicates a positive outlook from the investment bank regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71964792/barclays-initiates-sab-biotherapeutics-at-overweight-with-13-price-target?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-24T17:11:46", "published_display": "24 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 By Investing.com", "summary": "Barclays has initiated coverage on SAB Biotherapeutics Inc. (NASDAQ: SABS) with an Overweight rating and a $13 price target, citing the significant potential of its lead candidate, SAB-142, for type 1 diabetes prevention. The firm believes SAB-142 could address a market exceeding", "url": "https://ng.investing.com/news/stock-market-news/barclays-initiates-sab-biotherapeutics-stock-at-overweight-pt-13-93CH-2571809", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T15:09:59", "published_display": "24 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13", "summary": "Barclays has initiated coverage on SAB Biotherapeutics Inc. (NASDAQ:SABS) with an Overweight rating and a $13.00 price target, citing the potential of its lead candidate SAB-142 for type 1 diabetes prevention, which they estimate could exceed $4 billion in opportunity. Despite th", "url": "https://www.investing.com/news/analyst-ratings/barclays-initiates-sab-biotherapeutics-stock-at-overweight-pt-13-93CH-4757840", "source_name": "Investing.com", "published_at": "2026-06-24T11:40:06", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics Inc (SABS) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" score for SAB Biotherapeutics Inc (SABS) as part of TradingKey's stock analysis. As of June 23, 2026, the company's institutional confidence score is 7.00. The article details major institutional shareholders and their sharehold", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sabs/sentiment", "source_name": "TradingKey", "published_at": "2026-06-23T02:11:11", "published_display": "23 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) 44th Annual J.P. Morgan Healthcare Conference Summary", "summary": "SAB Biotherapeutics presented an overview of its strategic vision and clinical focus for its lead drug, SAB-142, at the 44th Annual J.P. Morgan Healthcare Conference. The drug, a fully human anti-thymocyte immunoglobulin, is in a pivotal Phase II-B trial for type 1 diabetes and a", "url": "https://quartr.com/events/sab-biotherapeutics-inc-sabs-44th-annual-j-p-morgan-healthcare-conference_FPWAfxVL", "source_name": "Quartr", "published_at": "2026-06-19T12:40:59", "published_display": "19 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article attempts to provide a revenue breakdown for SAB Biotherapeutics Inc (SABS) but states that the relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder page o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sabs/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T05:39:09", "published_display": "19 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of SAB Biotherapeutics Inc (SABS), listing major shareholders like Vivo Capital, LLC and Commodore Capital LP, and categorizing shareholder types. It also provides a historical overview of institutional shareholding from 2023Q4 to 20", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sabs/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T04:39:09", "published_display": "19 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics shareholders elect directors and approve auditor at annual meeting", "summary": "SAB Biotherapeutics shareholders elected four Class II directors\u2014Dr. David Zaccardelli, Katie Ellias, David Link, and Andrew Moin\u2014and ratified EisnerAmper LLP as their independent public accounting firm for the fiscal year ending December 31, 2026, at the company's 2026 Annual Me", "url": "https://www.investing.com/news/sec-filings/sab-biotherapeutics-shareholders-elect-directors-and-approve-auditor-at-annual-meeting-93CH-4751171", "source_name": "Investing.com", "published_at": "2026-06-19T01:39:32", "published_display": "19 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Adjusts Price Target on SAB Biotherapeutics to $16 From $14, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/chardan-adjusts-price-target-sab-105123281.html", "source_name": "MT Newswires", "published_at": "2026-06-17T10:51:23+00:00", "published_display": "17 Jun 2026 10:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies raises SAB Biotherapeutics price target on FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPeDh6OGIzSUlFdXNpZmxtZHR4UEdJRUVwX3FaQS11Y0ZIeE5GVFltNGtGRnZNTUxGMzZaRkhtRVRuS2o3R3pfMnZuMHA5UFlxbDBic0x0NFZ3OVprU0RVSWFFYlJ3cmV3ZmJrQ0RYdDhrRFZKSlBxaDR1c05QVHloS0RCREpfZkJQOTY1V2pLT2Q0aENfZEJvTTByb01YMkp6MXQ1dVFQcDVmWGxrZ21rSHRTRS1CdWV4enU1UWhxVTE0c0k?oc=5", "source_name": "Investing.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SABS - SAB Biotherapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE0tNmltakhIblRrcHNmNENoSWhNYWUzbkJ2bG9EVnRZWDZDTkRHcnViUHBFUUttRnlIN29ZaEFsb3NKUXN2WGc?oc=5", "source_name": "Finviz", "published_at": "2026-05-29T12:43:39+00:00", "published_display": "29 May 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citigroup-initiates-sab-biotherapeutics-buy-105511656.html", "source_name": "MT Newswires", "published_at": "2026-05-22T10:55:11+00:00", "published_display": "22 May 2026 10:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Initiates SAB Biotherapeutics at Buy With $11 Price Target", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/jefferies-initiates-sab-biotherapeutics-buy-100833405.html", "source_name": "MT Newswires", "published_at": "2026-05-20T10:08:33+00:00", "published_display": "20 May 2026 10:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQQ2FVcEIwYlRuWmFaMEtjNFdoTDRYcnZiT2ZhSlJVUUh3TVNjRU9mZEdJei0yWEdHVC01ZTNWWUdVM0RsRXhteElHSVNIYWVQZGpiQnpWUDVYbmZVX0NWNndGYWRXRXFTREZDaFFDbndJbkJLX01QRURoMGZubkotSE1iU3ZyZUR6ZXdmdzRveVFLRHRQcWlDV0J0VEtVRXpDUDYtbQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRNA, INO, SABS, NVAX Stocks Jump Premarket: Deadly Hantavirus Reaches US After Cruise Ship Outbreak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOd0VqbG16c1dPY0swVTFUVVkzRjU2ellTUGlxVmFwY1V6S21WZ1FxOU5rYk1HWlltMlpBOXliN0lxNzZEX21jeXBKNGNSVUpfZUhabDBZcEdsLUxKQ01QWHUzMmN0OFFneEhSeTZkZW5uSDUyNEdQOGxfTUF4VmZETHFCYm01bDhIYTFERnl1MkM5djIxYUNGbHhWbWl3ck1XS3k5cmYtR3ItUDZKVUxqTjdxYm92Q0xnWDktb0lQNXQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-11T08:25:52+00:00", "published_display": "11 May 2026 08:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdXYtRGl6NTZ0aV8wQWxiY0ZwaVFTTzRZbkxLcnNFRnMyWmdrMVFEaDJjdHlWWVNZeEJXT0VqU19QVHBlWTNBV29EX182REkteG1rcm5ZTldaZzBhZDlLRkJ0UW1ELUM3T08tLVluN1VsYS01X29NVU5adkxiS1Q1cnlUYzI2X0xmdEQwUk9qc0FkOXJFOVRFa2l1bUJUY3NJX1hjQmZKZ0EzRVlpelhGUmg3UmZRUjdz?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $SABS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFBkdFM5U19IN05VeUh4VDBJcTNxRDFMU0FFNDA3LUgtTVpKdTFUelltMWVOSTdmUHNiRlBkQnVRUFVRWHZZQmZGNzUwU1NZTUdROWdKUV9Bakg3eUU2SElIcmhBQ0diQS1I?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-10T02:21:07+00:00", "published_display": "10 Jul 2025 02:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) Stock Chart and Price History 2026 $SABS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE4tZU1uVzdKSjdTa2NlRzR6Z1cyeDdFVDN3S0NQZmhwTXhjZFVzY25DYTNrbEc5WFRCOXMtUDhLRDhhODU2dC1IQ1I0VzNuNXhQV05Ob2Vhc3BhdDFwcUZBM2Jn?oc=5", "source_name": "MarketBeat", "published_at": "2021-10-25T17:14:21+00:00", "published_display": "25 Oct 2021 17:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SAB Biotherapeutics (SABS) Stock Price, News & Analysis $SABS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE84ZndvdlZSUlZ5ME9TR2N1LXVOYmlmNFpWOEpOVk94MUdqOFh4VGJReGhCbzE1S0NJNTZxWVdBWkhjMjBzQnV0TFJUal9uV1Y3VlU4VUZiZU5OQQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-10-25T16:41:46+00:00", "published_display": "25 Oct 2021 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 48, "sentiment_summary": {"positive": 20, "negative": 1, "neutral": 27, "score": 58, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "analyst", "label": "Analyst action", "weight": 6.05, "count": 11}, {"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 3.82, "latest_week": "2026-07-10", "one_week_move": -2.6, "four_week_move": 14.7, "twelve_week_move": -0.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.145836, "market_dynamics_buy_signal": false, "relative_strength": -2.18082, "fair_value_gap": -3.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 44.6667, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.6% over one week, +14.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 9}, {"label": "Market source", "count": 8}, {"label": "MarketBeat", "count": 5}, {"label": "Investing.com", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Stock Titan", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 11}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.6% over one week, +14.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment"}], "updated_at": "2026-07-16T19:30:39.407251+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}